Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters

(2023) Ai-ris Y. Collier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster

(2023) Qian Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

(2022) Hung Fu Tseng et al.   NATURE MEDICINE

Homologous and Heterologous Covid-19 Booster Vaccinations

(2022) Robert L. Atmar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

(2022) Jill M. Ferdinands et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

(2022) Xinxue Liu et al.   JOURNAL OF INFECTION

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

(2022) Alasdair P S Munro et al.   LANCET INFECTIOUS DISEASES

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

(2022) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

(2022) Laith J. Abu-Raddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials

(2022) Qianqian Xin et al.   Nature Communications

Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study

(2022) Ramandip Grewal et al.   BMJ-British Medical Journal

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

(2022) C. Sabrina Tan et al.   JAMA Network Open

Antibody response 6 months after the booster dose of Pfizer in previous recipients of CoronaVac

(2022) Maria Francilene Souza Silva et al.   JOURNAL OF MEDICAL VIROLOGY

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance

(2021) Sue Pavord et al.   BMJ-British Medical Journal